Personalized treatment approaches for pancreatic cancer subtypes
Tailoring Therapy to Pancreatic Cancer Subtypes
['FUNDING_R01'] · FRED HUTCHINSON CANCER CENTER · NIH-11062949
This study is looking at how to create better treatments for pancreatic cancer by figuring out the different types of the disease and seeing how they respond to specific medications, so that patients can receive more personalized and effective care.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11062949 on ClinicalTrials.gov |
What this research studies
This research focuses on developing tailored therapies for pancreatic ductal adenocarcinoma (PDA) by identifying and targeting specific subtypes of the cancer. The study aims to optimize combinations of MEK and ERK inhibitors based on the unique characteristics of the Classical and Quasi-Mesenchymal PDA subtypes. By using preclinical models, the researchers will explore how these subtypes respond differently to treatments, potentially leading to more effective and tolerable therapies for patients. The goal is to improve patient outcomes by personalizing treatment strategies based on the subtype of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those whose tumors fall into the Classical or Quasi-Mesenchymal subtypes.
Not a fit: Patients with pancreatic cancer subtypes not addressed in this research, or those with advanced disease that is not amenable to targeted therapies, may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with pancreatic cancer, improving their chances of survival.
How similar studies have performed: Previous research has shown promise in using subtype-based approaches for cancer treatment, suggesting that this method could lead to significant advancements in managing pancreatic cancer.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COLLISSON, ERIC — FRED HUTCHINSON CANCER CENTER
- Study coordinator: COLLISSON, ERIC
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.